Non Small Cell Lung Cancer Clinical Trials in Baltimore, Maryland

23 studies are recruiting for non small cell lung cancer in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Baltimore, Maryland
    Locations
    328 in total
    Run by
    AstraZeneca

    See if you can join NCT06692738 on ClinicalTrials.gov

  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Baltimore, Maryland
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  3. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    16 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT07154290 on ClinicalTrials.gov

  4. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore, Maryland
    Locations
    280 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

  5. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    38 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06343402 on ClinicalTrials.gov

  6. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Johns Hopkins University of Medicine, Baltimore, Maryland
    Locations
    153 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov

  7. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

    This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    8 in total
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06745882 on ClinicalTrials.gov

  8. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    260 in total
    Run by
    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

  9. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage
    Phase 2
    Ages
    18 to 95
    Site
    Research Site, Baltimore, Maryland
    Locations
    97 in total
    Run by
    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

  10. Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

    The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhib…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    University of Maryland, Baltimore, Maryland
    Locations
    14 in total
    Run by
    InSightec

    See if you can join NCT05317858 on ClinicalTrials.gov

  11. A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

    Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This stud…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland
    Locations
    41 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06731907 on ClinicalTrials.gov

  12. DK222 Study at Hopkins

    This Phase 1 clinical trial will test a new drug called [18F]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. [18F]DK222 is designed to attach strongly and specifically to a prot…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins Hospital, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT07140315 on ClinicalTrials.gov

  13. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    45 in total
    Run by
    BioNTech SE

    See if you can join NCT05142189 on ClinicalTrials.gov

  14. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Maryland, Baltimore, Maryland
    Locations
    47 in total
    Run by
    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

  15. A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

    This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of vario…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Research Site, Baltimore, Maryland
    Locations
    83 in total
    Run by
    AstraZeneca

    See if you can join NCT07098338 on ClinicalTrials.gov

  16. A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

    The purpose of this research study is to find out if adding radiation prior to chemoimmunotherapy and surgery is effective for people with non-small cell lung cancer (NSCLC) who have the potential for surgery. Standard of Care Chemoimmunotherapy: For this study, standard of care chemotherapy will b…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    4 in total
    Run by
    University of Maryland, Baltimore

    See if you can join NCT06800339 on ClinicalTrials.gov

  17. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Maryland Medical Center, Baltimore, Maryland
    Locations
    26 in total
    Run by
    Teligene US

    See if you can join NCT05168566 on ClinicalTrials.gov

  18. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins University, Baltimore, Maryland
    Locations
    14 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

  19. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Maryland Medical Center, Baltimore, Maryland
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  20. KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

    This is a single institution, Phase 1 study for patients with Stage III/IV unresectable Kirsten rat sarcoma (KRAS) mutated NSCLC to evaluate safety of the pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with polyinosinic-polycytidylic acid (poly-ICLC) adjuvant in combination with chemoimm…

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Johns Hopkins University, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT05254184 on ClinicalTrials.gov

  21. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Maryland, Baltimore, Maryland
    Locations
    58 in total
    Run by
    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

  22. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Baltimore, Maryland
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  23. First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

    This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. Th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Run by
    A&G Pharmaceutical Inc.

    See if you can join NCT05627960 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.